Anti-Müllerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
23
6
2020
Statut:
ppublish
Résumé
Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Müllerian hormone) is currently considered the best measure of ovarian reserve.A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level.The MD1 group shows a significant decrease of AMH values (median 0.7 ng/mL; range 0 - 4.9 ng/mL) compared with age-matched healthy controls (P < .01). AMH levels were similar between patients and controls in terms of females with MD2 (P = .98), FSHD (P = .55) and cDMD (P = .60).This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.
Identifiants
pubmed: 32502004
doi: 10.1097/MD.0000000000020523
pii: 00005792-202006050-00042
pmc: PMC7306369
doi:
Substances chimiques
Biomarkers
0
Anti-Mullerian Hormone
80497-65-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20523Références
J Assist Reprod Genet. 2008 Jan;25(1):1-5
pubmed: 18202909
Reprod Biomed Online. 2014 Jul;29(1):94-101
pubmed: 24813161
J Endocrinol Invest. 1990 May;13(5):375-9
pubmed: 2116473
Hum Reprod. 2006 Dec;21(12):3103-7
pubmed: 16923748
Hum Reprod. 2006 Jan;21(1):175-82
pubmed: 16199430
Int J Appl Basic Med Res. 2012 Jan;2(1):17-9
pubmed: 23776802
Fertil Steril. 2009 Mar;91(3):705-14
pubmed: 18321493
Clin Endocrinol (Oxf). 2019 Jun;90(6):827-833
pubmed: 30868616
Int J Fertil Steril. 2016 Jan-Mar;9(4):411-5
pubmed: 26985328
PLoS One. 2011;6(7):e22024
pubmed: 21789206
Fertil Steril. 2002 Feb;77(2):357-62
pubmed: 11821097
Hum Reprod Update. 2014 Sep-Oct;20(5):688-701
pubmed: 24821925
Clin Biochem. 2018 Dec;62:2-10
pubmed: 29555319
Nat Commun. 2016 Jan 12;7:10055
pubmed: 26753790
J Assist Reprod Genet. 2018 May;35(5):777-783
pubmed: 29536384
Hum Reprod. 2003 Feb;18(2):323-7
pubmed: 12571168
J Clin Endocrinol Metab. 2012 Dec;97(12):4650-5
pubmed: 22993032
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9348-53
pubmed: 12878721
Phys Ther. 1992 Feb;72(2):115-22; discussion 122-6
pubmed: 1549632
Fertil Steril. 2008 Sep;90(3):737-43
pubmed: 17923131
Neurology. 2018 Jan 16;90(3):e254-e260
pubmed: 29273686
Reprod Fertil Dev. 2018 Aug;30(9):1192-1203
pubmed: 29533759
Hum Reprod Update. 2016 Nov;22(6):709-724
pubmed: 27566840
Reprod Biomed Online. 2010 May;20(5):610-8
pubmed: 20231114
Endocrinol Diabetes Metab Case Rep. 2018 Jan 18;2018:
pubmed: 29367875
Front Neurol. 2018 Jun 19;9:446
pubmed: 29973905
Endocr Rev. 2009 Aug;30(5):465-93
pubmed: 19589949
Hum Reprod. 2008 Jul;23(7):1654-60
pubmed: 18408243
Acta Obstet Gynecol Scand. 2012 Nov;91(11):1252-60
pubmed: 22646322
J Clin Endocrinol Metab. 2010 Nov;95(11):5003-10
pubmed: 20719830
Eur J Obstet Gynecol Reprod Biol. 2012 Aug;163(2):180-4
pubmed: 22579227